CoChat
Sign Up
Cited by 22Menopause: Health Impacts and TreatmentsLipoproteins and Cardiovascular HealthLipid metabolism and disorders

Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.

Open access
Carr, Molly C., Knopp, Robert H., Brunzell, John D., Wheeler, Barbara S., Zhu, Xiaodong, Lakshmanan, Mark, Rosen, Amy S., Anderson, Pamela W.·2005·Diabetes Care
DOI 10.2337/diacare.28.7.1555
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Raloxifene hydrochloride is a selective estrogen receptor modulator that to date has not been shown to cause hypertriglyceridemia in normal, diabetic, or hypertriglyceridemic women. This study was designed to assess the effect of raloxifene on serum triglycerides in postmenopausal women who have a history of increased hypertriglyceridemia with oral estrogen therapy. RESEARCH DESIGN AND METHODS: This was a single-center, uncontrolled, open-label study investigating the effects of 8 weeks of raloxifene (60 mg/day) therapy on plasma lipids. The study subjects were 12 postmenopausal women, ages 49-73 years, with a documented history of oral estrogen-induced hypertriglyceridemia (serum triglycerides > or =3.39 mmol/l [> or =300 mg/dl]). RESULTS: At week 2 of the study, three (25%) of the subjects withdrew from the trial because they developed marked hypertriglyceridemia (>or =11.3 mmol/l [> or =1,000 mg/dl]) during raloxifene therapy. These three women had higher baseline triglyceride and glucose levels, were not being treated with lipid-lowering agents, and were more likely to have diabetes than the other study subjects. The remaining nine patients (75%) completed the 8-week trial and experienced a nonsignificant increase in mean triglyceride levels from baseline to end point. Raloxifene treatment also resulted in a significant 16% decrease in hepatic lipase activity and a 26% increase in HDL(2) levels (P = 0.013 and 0.03, respectively). CONCLUSIONS: Patients with a previous history of hypertriglyceridemia on oral estrogen therapy should have serum triglyceride levels monitored closely after beginning raloxifene therapy and may even require fibrate therapy before beginning raloxifene.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.28.7.1555

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tamoxifen can increase triglyceride levels; the effect is less pronounced with raloxifene, but raloxifene can increase levels in women with an underlying propensity to hypertriglyceridemia.

    “Tamoxifen, a selective estrogen receptor modulator, can also increase triglyceride levels.The effect is less pronounced with raloxifene, but that drug can increase levels in women with an underlying propensity to hypertriglyceridemia (89, 90).”

    From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [90]

    The discussion (page unavailable) lists tamoxifen among drugs that can exacerbate hypertriglyceridemia and says raloxifene’s effect on triglycerides is generally neutral. The study’s conclusions report marked triglyceride increases in 3 of 12 women with a history of estrogen-associated hypertriglyceridemia. The paper does not directly compare the size of tamoxifen’s and raloxifene’s effects, so the claim that raloxifene’s effect is less pronounced is not established by this source. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • Selective estrogen-receptor modulators have less impact on the lipid profile than oral hormone therapy in the absence of hypertriglyceridemia with estrogen therapy.

    “Selective estrogen-receptor modulators have less impact on the lipid profile than oral hormone therapy in the absence of hypertriglyceridemia with estrogen therapy.”

    From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [121]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Carr, M. C., Knopp, R. H., Brunzell, J. D., Wheeler, B. S., Zhu, X., Lakshmanan, M., Rosen, A. S., & Anderson, P. W.
Affiliations
  • Northwestern University (US)
  • University of Washington (US)
  • Eli Lilly (United States) (US)
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2005-07-01
Volume
28
Issue
7
Pages
1555-1561
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.28.7.1555
OpenAlex
W2164216188
Cited by
22
References
50
Citations by year
2020: 2 · 2017: 2 · 2015: 2 · 2013: 2 · 2012: 3
FWCI
0.83
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • National Institutes of Health
  • U.S. Food and Drug Administration
  • National Heart, Lung, and Blood Institute (HL 64322, R01HL064322)
  • National Center for Research Resources (K23RR16067, K23RR016067)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
raloxifene, hypertriglyceridemia, oral estrogen therapy, selective estrogen receptor modulators, postmenopausal women, hepatic lipase, HDL2, fibrate therapy, diabetes mellitus
MeSH terms
Aged, Apolipoproteins, Cholesterol, Female, Humans, Lipoproteins, Middle Aged, Patient Compliance, Triglycerides, Hypertriglyceridemia, Estrogen Replacement Therapy, Postmenopause, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review